Diferencia entre revisiones de «Inhibidor de la tirosina quinasa»
Sin resumen de edición |
m Revertidos los cambios de 166.210.125.245 a la última edición de VolkovBot |
||
Línea 1: | Línea 1: | ||
Un '''inhibidor de la tirosin kinasa''' es un tipo de [[inhibidor enzimatico]] que bloquea especificamente la accion de una o mas [[ |
Un '''inhibidor de la tirosin kinasa''' es un tipo de [[inhibidor enzimatico]] que bloquea especificamente la accion de una o mas [[kinasas proteica]]s. Por consiguiente, estas pueden ser subdivididas o caracterizadas por los [[aminoacido]]s en los cuales la fosporilacion es inhibida: |
||
la mayoria de kinasas actuan tanto en la serina como en la treonina, |
la mayoria de kinasas actuan tanto en la serina como en la treonina, as the [[tyrosine kinase]]s act on tyrosine, and a number ([[dual-specificity kinase]]s) act on all three. There are also protein kinases that phosphorylate other amino acids, including [[histidine kinase]]s that phosphorylate histidine residues.{{Fact|date=March 2009}} |
||
They can interfere with the repair of DNA double-strand breaks.<ref name="pmid16707462">{{cite journal |author=Zhao Y, Thomas HD, Batey MA, ''et al.'' |title=Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441 |journal=Cancer Res. |volume=66 |issue=10 |pages=5354–62 |year=2006 |month=May |pmid=16707462 |doi=10.1158/0008-5472.CAN-05-4275 |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=16707462}}</ref> |
|||
==Clinical use== |
==Clinical use== |
Revisión del 17:48 25 nov 2009
Un inhibidor de la tirosin kinasa es un tipo de inhibidor enzimatico que bloquea especificamente la accion de una o mas kinasas proteicas. Por consiguiente, estas pueden ser subdivididas o caracterizadas por los aminoacidos en los cuales la fosporilacion es inhibida: la mayoria de kinasas actuan tanto en la serina como en la treonina, as the tyrosine kinases act on tyrosine, and a number (dual-specificity kinases) act on all three. There are also protein kinases that phosphorylate other amino acids, including histidine kinases that phosphorylate histidine residues.[cita requerida]
They can interfere with the repair of DNA double-strand breaks.[1]
Clinical use
Kinase inhibitors such as dasatinib are often used in the treatment of cancer and inflammation.[cita requerida] The novel kinase inhibitor PLX5568 is currently in clinical trials for treatment of polycystic kidney disease as well as pain.[2]
Some of the kinase inhibitors used in treating cancer are inhibitors of tyrosine kinase.[3] The effectiveness of kinase inhibitors on various cancers can vary from patient to patient[4].
Examples
Currently there are several drugs launched that target protein kinases and the receptors that activate them:
Name | Target | Company | Class | FDA Approval |
Bevacizumab | VEGF | Genentech | Monoclonal antibody | 2004 Colorectal |
BIBW 2992 | EGFR/Erb2 | Boehringer Ingelheim | Small molecule | |
Cetuximab | Erb1 | Imclone/BMS | Monoclonal antibody | 2006 Mar (SCCHN) |
Imatinib | Bcr-Abl | Novartis | Small molecule | 2001 (CML) |
Trastuzumab | Erb2 | Genentech/Roche | Monoclonal antibody | 1998 |
Gefitinib | EGFR | AstraZeneca | Small molecule | ?? |
Ranibizumab | VEGF | Genentech | Monoclonal antibody | 2006 (AMD) |
Pegaptanib | VEGF | OSI/Pfizer | Small molecule | 2004 (AMD) |
Sorafenib | multiple targets | Onyx/Bayer | Small molecule | 2005 Dec (kidney) |
Dasatinib | multiple targets | BMS | Small molecule | only Ph 1 ?? |
Sunitinib | multiple targets | Pfizer | Small molecule | 2006 Jan (RCC & GIST) |
Erlotinib | Erb1 | Genentech/Roche | Small molecule | 2005 Nov ? |
Nilotinib | Bcl-Abr | Novartis | Small molecule | 2007 |
Lapatinib | Erb1/Erb2 | GSK | Small molecule | 2007 (HER2+ Breast) |
Panitumumab | EGFR | Amgen | Monoclonal antibody | 2006 |
Vandetanib | RET/VEGFR/EGFR | AstraZeneca | Small molecule | only Ph 3 ? |
E7080 | VEGFR2/VEGFR2 | Eisai Co. | Small molecule |
References
- ↑ Zhao Y, Thomas HD, Batey MA, et al. (May de 2006). «Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441». Cancer Res. 66 (10): 5354-62. PMID 16707462. doi:10.1158/0008-5472.CAN-05-4275.
- ↑ «Plexxikon Initiates Phase 1 Trial for PLX5568».
- ↑ «Definition of tyrosine kinase inhibitor - NCI Dictionary of Cancer Terms».
- ↑ http://www.nature.com/nrd/journal/v8/n9/full/nrd2871.html "Factors underlying sensitivity of cancers to small-molecule kinase inhibitors"
External links
- MeSH: Protein+kinase+inhibitors (en inglés)
- IC50 values for common inhibitors
- KinaseCentral.com
- "Chemical structures and known kinase targets for clinically approved kinase inhibitors" Nature.com
Plantilla:Enzyme inhibition
Plantilla:Extracellular chemotherapeutic agents
Plantilla:Chemotherapeutic agents